[go: up one dir, main page]

PE20020783A1 - Uso de polisacaridos zwitterionicos para la modulacion especifica de procesos inmunitarios - Google Patents

Uso de polisacaridos zwitterionicos para la modulacion especifica de procesos inmunitarios

Info

Publication number
PE20020783A1
PE20020783A1 PE2001001223A PE2001001223A PE20020783A1 PE 20020783 A1 PE20020783 A1 PE 20020783A1 PE 2001001223 A PE2001001223 A PE 2001001223A PE 2001001223 A PE2001001223 A PE 2001001223A PE 20020783 A1 PE20020783 A1 PE 20020783A1
Authority
PE
Peru
Prior art keywords
polymer
forcing
subunit
formunication
adduciration
Prior art date
Application number
PE2001001223A
Other languages
English (en)
Inventor
Dennis L Kasper
Ying Wang
Michael H Roehrl
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of PE20020783A1 publication Critical patent/PE20020783A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)

Abstract

SE REFIERE A UN POLIMERO INMUNOMODULADOR QUE COMPRENDE: UN POLIMERO DE MULTIPLES UNIDADES REPETITIVAS COMO UN TETRAMERO CON UNA ESTRUCTURA DE SUBUNIDADES -((-)S1-S2-S3-S4(+))-,(DE 3 HASTA 20 UNIDADES), LA CARGA NEGATIVA (-) PUEDE SER POR UN CARBOXILO, FOSFATO, FOSFONATO; EL AMINO LIBRE EN LA CUARTA SUBUNIDAD DE UNA UNIDAD ES MENOR DE 32A° DESDE LA PORCION AMINO LIBRE SIGUIENTE MAS CERCANA EN LA CUARTA SUBUNIDAD DE OTRA UNIDAD; LAS SUBUNIDADES SE SELECCIONAN DE MONO O DISACARIDOS, AMINOACIDO, DIPEPTIDO, NUCLEOTIDO, CICLOALQUILO C15-C18, ARILO C15-C18 QUE PUEDEN SER OPCIONALMENTE RAMIFICADAS; SIENDO EL POLISACARIDO PSA2. TAMBIEN SE REFIERE A UN POLIMERO CUYA CONFORMACION DE TRIDIMENSIONAL (HELICE) DE LAS CARGAS POSITIVAS Y NEGATIVAS SON ACCESIBLES AL SOLVENTE, CON MULTIPLES SITIOS DE ACOPLAMIENTO DE 10A° DE ANCHO Y 5A° DE PROFUNDIDAD; Y EL SITIO DE ACOPLAMIENTO TIENE 10A° DE LARGO, ESTA CONSTRUIDO Y DISPUESTO PARA UNIRSE BAJO CONDICIONES FISIOLOGICAS A UNA HELICE a DE UN POLIPEPTIDO (COMPLEJO DE HISTOCOMPATIBILIDAD, RECEPTOR DE ANTIGENO DE CELULAS T) CON UNA AFINIDAD DE AL MENOS 10-3M-1. EL POLIMERO INMUNOMODULADOR TRIDIMENSIONAL ALTERA LA FUNCION CELULAR INMUNITARIA INDUCIENDO LA PRODUCCION DE CITOQUINAS, ACTIVANDO LAS CELULAS INMUNITARIAS SUPRIMIENDO LA PRODUCCION DE ANTICUERPOS DE INMUNOGLOGULINA G Y PUEDEN SER UTILES PARA INDUCIR LA PROTECCION CONTRA LA FORMACION DE ABSCESOS, REDUCIR LA FORMACION DE ADHESIONES QUIRURGICAS
PE2001001223A 2000-12-05 2001-12-05 Uso de polisacaridos zwitterionicos para la modulacion especifica de procesos inmunitarios PE20020783A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25174700P 2000-12-05 2000-12-05

Publications (1)

Publication Number Publication Date
PE20020783A1 true PE20020783A1 (es) 2002-09-05

Family

ID=22953235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001223A PE20020783A1 (es) 2000-12-05 2001-12-05 Uso de polisacaridos zwitterionicos para la modulacion especifica de procesos inmunitarios

Country Status (9)

Country Link
US (2) US7629330B2 (es)
EP (1) EP1365774A2 (es)
JP (2) JP4431311B2 (es)
AR (1) AR036984A1 (es)
AU (1) AU2002228890A1 (es)
CA (1) CA2436666C (es)
PE (1) PE20020783A1 (es)
SV (1) SV2003000753A (es)
WO (1) WO2002045708A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
PL207835B1 (pl) * 2000-02-17 2011-02-28 Garnett Sposób kontrolowania wzrostu populacji organicznych szkodników wodnych oraz wzrostu populacji mięczaków w systemach wodnych
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
AU2003218144B2 (en) * 2002-03-13 2008-08-14 The Brigham And Women's Hospital, Inc. Method for overexpression of zwitterionic polysaccharides
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US6970791B1 (en) * 2003-05-23 2005-11-29 Verachem, Llc Tailored user interfaces for molecular modeling
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US20090136547A1 (en) * 2005-08-24 2009-05-28 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
WO2007092451A2 (en) * 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2217250A4 (en) * 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
US20110002965A1 (en) * 2007-11-09 2011-01-06 Round June L Immunomodulating compounds and related compositions and methods
JP2012524910A (ja) * 2009-04-23 2012-10-18 カリフォルニア インスティチュート オブ テクノロジー 免疫調節物質の同定方法及びシステム
US8580278B2 (en) 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
EP3978598B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
CA2911826C (en) * 2013-05-10 2022-08-23 California Institute Of Technology Probiotic prevention and treatment of colon cancer
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
KR102473378B1 (ko) * 2017-08-31 2022-12-01 엘지디스플레이 주식회사 유기 발광 표시 장치
CN111171114B (zh) * 2020-01-17 2022-08-12 遵义医科大学 一种膦酸酯二肽类化合物及其应用
CN113327649B (zh) * 2021-06-30 2023-06-16 青岛科技大学 一种基于分子动力学的半纤维素溶解机理的分析方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS56128721A (en) 1980-03-12 1981-10-08 Eisai Co Ltd Antiallergic agent
SE456346B (sv) 1984-07-23 1988-09-26 Pharmacia Ab Gel for att forhindra adhesion mellan kroppsvevnader och sett for dess framstellning
US4619995A (en) 1984-12-24 1986-10-28 Nova Chem Limited N,O-carboxymethyl chitosan and preparative method therefor
EP0229829B1 (en) 1985-07-12 1995-02-22 New York University Immunogenic peptide antigen corresponding to plasmodium vivax circumsporozoite protein
US4684727A (en) 1985-07-29 1987-08-04 Schering Corporation Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
US4819617A (en) 1986-09-04 1989-04-11 University Of Florida Viscoelastic material for ophthalmic surgery
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
DE3704389A1 (de) 1987-02-12 1988-08-25 Blutspendedienst Dt Rote Kreuz Verfahren zur herstellung von lymphokinen durch induktion lymphoider zellen
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5215896A (en) 1987-03-20 1993-06-01 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
US6174999B1 (en) 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5140016A (en) 1988-05-31 1992-08-18 University Of Florida Method and composition for preventing surgical adhesions using a dilute solution of polymer
US5126141A (en) 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5196510A (en) 1988-12-29 1993-03-23 Cytogen Corporation Molecular recognition units
US5158939A (en) 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
HU218146B (hu) 1989-12-14 2000-06-28 National Research Council Of Canada Továbbfejlesztett meningokokkusz-poliszacharid-konjugátum vakcina
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5130417A (en) 1990-04-30 1992-07-14 Washington University Entamoeba histolytical immunogenic protein and cdna clone
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
GB2254083A (en) 1991-03-28 1992-09-30 Italfarmaco Spa Anticoagulants from e.coli saccharide
GR920100122A (el) 1991-04-05 1993-03-16 Ethicon Inc Πολυσακχαρίτες οι οποίοι περιέχουν καρβοξύλιο με σταυροειδείς δεσμούς δια την πρόληψιν της προσφύσεως.
US5705178A (en) 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
JP4163251B2 (ja) * 1992-09-24 2008-10-08 ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド グループｂストレプトコッカス・タイプ▲ｉｉ▼およびタイプ▲ｖ▼多糖−蛋白質接合ワクチン
AU1297995A (en) 1993-11-26 1995-06-13 Lawrence B Hendry Design of drugs involving receptor-ligand-dna interactions
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
WO1996014077A1 (en) 1994-11-02 1996-05-17 Trophix Pharmaceuticals, Inc. Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5679658A (en) 1995-05-08 1997-10-21 Chitogenics, Inc. N,O-carbonxymethylchitosan for prevention of surgical adhesions
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
EP1061949B1 (en) 1998-03-03 2009-07-15 University of Southern California Cytokines and mitogens to inhibit graft-versus-host disease
WO1999052560A1 (en) 1998-04-13 1999-10-21 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
EP1459757A1 (en) 1999-04-02 2004-09-22 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
EP1169045A2 (en) 1999-04-02 2002-01-09 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP2001055335A (ja) 1999-08-18 2001-02-27 Toshio Sato アレルギー性皮膚疾患治療剤
US6995237B1 (en) 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
WO2002055091A1 (fr) 2001-01-12 2002-07-18 Amato Pharmaceutical Products,Ltd. Agents antiallergiques
EP1494687A2 (en) 2002-03-08 2005-01-12 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
AU2003218144B2 (en) * 2002-03-13 2008-08-14 The Brigham And Women's Hospital, Inc. Method for overexpression of zwitterionic polysaccharides
EP1638581A2 (en) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS
US20100311686A1 (en) * 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis

Also Published As

Publication number Publication date
JP2009102305A (ja) 2009-05-14
AR036984A1 (es) 2004-10-20
US8008276B2 (en) 2011-08-30
WO2002045708A2 (en) 2002-06-13
EP1365774A2 (en) 2003-12-03
WO2002045708A9 (en) 2003-11-06
CA2436666A1 (en) 2002-06-13
JP2004536028A (ja) 2004-12-02
JP4431311B2 (ja) 2010-03-10
WO2002045708A3 (en) 2003-09-04
US20040092433A1 (en) 2004-05-13
US7629330B2 (en) 2009-12-08
SV2003000753A (es) 2003-06-16
CA2436666C (en) 2013-05-21
AU2002228890A1 (en) 2002-06-18
US20090317410A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
PE20020783A1 (es) Uso de polisacaridos zwitterionicos para la modulacion especifica de procesos inmunitarios
AR026443A1 (es) Compuesto fosfato de aminoalquil glucosaminida y su uso como coadyuvantes e inmunoefectores
BR0212470A (pt) Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck
BR0007908A (pt) Sistema de transmissão elétrica e poço multilateral, e, módulo transportador de equipamento do tipo luva para uso em um poço multilateral e um sistema de transmissão elétrica
DK0814838T3 (da) Antigenpræsenterende system og aktivering af T-celler
DE50005900D1 (de) Aktives instrument zur positionsbestimmung bei navigationssystemen zur unterstützung chirurgischer eingriffe
DK0726952T3 (da) Receptor benævnt ACT-4 på overfladen af aktiverede T-celler
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
AR037899A1 (es) Vehiculo robotico y metodo para ensayos del suelo
CY1105500T1 (el) Αντιγονο και εμβολιο απο staphylococcus
TR200000115T2 (tr) Tüberkülozun immünoterapi ve teşhisi için bileşikler ve bu bileşiklerin kullanımı için yöntemler.
ES2105398T3 (es) Grapa hemostatica quirurgica.
ATE245970T1 (de) Ionisches konjugat zur verzoegerten freisetzung
WO2009039854A2 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
ATE295372T1 (de) Hydrophobisch-modifizierte hedgehog protein zusammensetzungen und verfahren
WO2000054730A3 (en) Compositions preparations and uses of human papillomavirus l1 protein
TWI268268B (en) Tool support
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
ES2056981T3 (es) Composiciones dotadas de una capacidad de penetracion mejorada.
CN108120836B (zh) 一种检测活细胞内Paxillin蛋白力传递的荧光生物探针
EP1012603A4 (en) FUNCTIONAL FRAGMENTS OF THE HIV-1 VPR PROTEIN AND A METHOD FOR ITS USE
EP0952772A4 (en) COMPOSITIONS AND METHODS OF USE OF SINGLE-NUCLEAR PHAGOCYTES TO REQUIRE AXONAL REGENERATION
ES2138440T3 (es) Polvos redispersables en agua de polimeros filmogenos preparados a partir de monomeros con insaturacion etilenica.
Melkonian The functional analysis of the flagellar apparatus in green algae
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.

Legal Events

Date Code Title Description
FC Refusal